CSRxP STATEMENT ON PRESIDENT TRUMP’S MOST FAVORED NATION EXECUTIVE ORDER
Administration Rightly Diagnoses Big Pharma’s Egregious Pricing Practices as… Read More
© 2025 CSRXP- All Rights Reserved
THEY SAID IT! RFK JR CALLS FOR REINING IN BIG PHARMA’S STAGGERING SPENDING ON DTC ADVERTISING OF PRESCRIPTION DRUGS
HHS Secretary Highlights How Big Pharma’s Marketing Strategies for… Read More
BIG PHARMA EARNINGS WATCH: NOVO NORDISK
Brand Name Manufacturer Previews New DTC Ad Campaign to Further Boost Sales of… Read More
BIG PHARMA EARNINGS WATCH: AMGEN AND ELI LILLY
Pharmaceutical Companies Continue Reporting Big Time Earnings While Continuing… Read More
CSRXP: PHARMA-BACKED PERA AND PREVAIL ACT WOULD FURTHER ENABLE PATENT ABUSE, UNDERMINE BIPARTISAN PROGRESS TOWARD GREATER COMPETITION
Lawmakers Should Focus on Market-Based Solutions That Hold Big Pharma… Read More
BIG PHARMA EARNINGS WATCH: ASTRAZENECA AND NOVARTIS
Big Pharma Giants Report Strong Earnings Beating Analysts’ Expectations… Read More
BIG PHARMA EARNINGS WATCH: ABBVIE, ROCHE, GILEAD, MERCK AND BRISTOL MYERS SQUIBB
Merck CEO Acknowledges Americans Paying Highest Drug Prices in the World as… Read More
CSRXP LAUNCHES SIX-FIGURE ADVERTISING CAMPAIGN TO HOLD BIG PHARMA ACCOUNTABLE FOR ANTICOMPETITIVE PRACTICES AND EGREGIOUS DRUG PRICING
Campaign Spoofs Big Pharma’s Direct-to-Consumer (DTC) Ads While Highlighting… Read More
DOSE OF REALITY: BIG PHARMA’S PATENT ABUSE EXTENDING MONOPOLIES, KEEPING PRICES HIGH ON GLP-1S
Novo Nordisk Alone Has Filed 320 Patents on Single Active Ingredient Behind… Read More
BIG PHARMA EARNINGS WATCH: JOHNSON & JOHNSON
Big Pharma Giant Johnson & Johnson Reports Earnings That Beating Wall… Read More
CSRXP STATEMENT ON U.S. SENATE AND U.S. HOUSE REINTRODUCTION OF Q1/Q2 REFORMS TO FOSTER GREATER COMPETITION, LOWER DRUG PRICES
Lawmakers Should Advance Bipartisan Solution to Crack Down on Anti-Competitive… Read More
THEY SAID IT! SENATE JUDICIARY CALLS OUT BIG PHARMA’S ANTI-COMPETITIVE PRACTICES THAT KEEP PRESCRIPTION DRUG PRICES HIGH
Senators on Both Sides of the Aisle Highlight Concerns with Big Pharma’s… Read More